MA55767A - Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate - Google Patents
Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarateInfo
- Publication number
- MA55767A MA55767A MA055767A MA55767A MA55767A MA 55767 A MA55767 A MA 55767A MA 055767 A MA055767 A MA 055767A MA 55767 A MA55767 A MA 55767A MA 55767 A MA55767 A MA 55767A
- Authority
- MA
- Morocco
- Prior art keywords
- methoxyspiro
- dimethylmorpholino
- indolin
- cyclopropane
- styryl
- Prior art date
Links
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 title 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837858P | 2019-04-24 | 2019-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55767A true MA55767A (fr) | 2022-03-02 |
Family
ID=72940551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055767A MA55767A (fr) | 2019-04-24 | 2020-04-23 | Forme cristalline s4 d'un inhibiteur de plk4 (1r,2s)-(e)-2-(3-(4-((cis-2,6-diméthylmorpholino)méthyl)styryl)- 1 h-imidazol-6- yl)-5'-méthoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12325700B2 (enExample) |
| EP (1) | EP3959209A4 (enExample) |
| JP (1) | JP7705351B2 (enExample) |
| KR (1) | KR20220004102A (enExample) |
| CN (1) | CN113966330B (enExample) |
| AU (1) | AU2020264143B2 (enExample) |
| BR (1) | BR112021021106A2 (enExample) |
| CA (1) | CA3137191A1 (enExample) |
| EA (1) | EA202192903A1 (enExample) |
| IL (1) | IL287394A (enExample) |
| MA (1) | MA55767A (enExample) |
| MX (1) | MX2021012993A (enExample) |
| SA (1) | SA521430647B1 (enExample) |
| SG (1) | SG11202111003UA (enExample) |
| TW (1) | TWI862582B (enExample) |
| WO (1) | WO2020215155A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220124177A (ko) | 2019-12-06 | 2022-09-13 | 유니버시티 헬스 네트워크 | 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법 |
| TWI926033B (zh) | 2021-05-11 | 2026-05-21 | 美商歐瑞克製藥公司 | 類ｐｏｌｏ激酶４抑制劑 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205328B2 (en) | 2002-10-21 | 2007-04-17 | Irm Llc | Oxindoles with anti-HIV activity |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| GB0606234D0 (en) | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
| BRPI0817315A2 (pt) | 2007-09-25 | 2015-03-17 | Takeda Pharmaceutical | Inibidores de quinase do tipo polo |
| EP2235004A4 (en) | 2007-12-21 | 2011-05-04 | Univ Health Network | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT |
| WO2010115279A1 (en) | 2009-04-06 | 2010-10-14 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| WO2010125004A1 (en) | 2009-04-29 | 2010-11-04 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor salts |
| TWI516262B (zh) | 2010-04-06 | 2016-01-11 | 健康網路大學 | 激酶抑制劑及以其治療癌症的方法 |
| CA2803446C (en) | 2010-07-02 | 2019-06-04 | University Health Network | Use of plk4 antagonists for treating pten mutant diseases |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| EP2766352B1 (en) | 2011-10-12 | 2018-06-06 | University Health Network (UHN) | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| TR201902875T4 (tr) * | 2013-10-18 | 2019-03-21 | Univ Health Network | Plk-4 inhibitörünün tuz ve kristal formları. |
| EA030089B1 (ru) | 2013-10-18 | 2018-06-29 | Юниверсити Хелс Нетуорк | Лечение рака поджелудочной железы |
-
2020
- 2020-04-23 EP EP20795605.3A patent/EP3959209A4/en active Pending
- 2020-04-23 MX MX2021012993A patent/MX2021012993A/es unknown
- 2020-04-23 CA CA3137191A patent/CA3137191A1/en active Pending
- 2020-04-23 KR KR1020217037777A patent/KR20220004102A/ko not_active Ceased
- 2020-04-23 US US17/605,108 patent/US12325700B2/en active Active
- 2020-04-23 TW TW109113591A patent/TWI862582B/zh active
- 2020-04-23 BR BR112021021106A patent/BR112021021106A2/pt unknown
- 2020-04-23 JP JP2021562948A patent/JP7705351B2/ja active Active
- 2020-04-23 WO PCT/CA2020/050535 patent/WO2020215155A1/en not_active Ceased
- 2020-04-23 SG SG11202111003UA patent/SG11202111003UA/en unknown
- 2020-04-23 AU AU2020264143A patent/AU2020264143B2/en active Active
- 2020-04-23 CN CN202080030678.8A patent/CN113966330B/zh active Active
- 2020-04-23 EA EA202192903A patent/EA202192903A1/ru unknown
- 2020-04-23 MA MA055767A patent/MA55767A/fr unknown
-
2021
- 2021-10-19 IL IL287394A patent/IL287394A/en unknown
- 2021-10-20 SA SA521430647A patent/SA521430647B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020264143B2 (en) | 2026-05-21 |
| SA521430647B1 (ar) | 2024-01-27 |
| KR20220004102A (ko) | 2022-01-11 |
| CN113966330B (zh) | 2024-09-13 |
| MX2021012993A (es) | 2021-12-10 |
| TW202104216A (zh) | 2021-02-01 |
| JP7705351B2 (ja) | 2025-07-09 |
| CN113966330A (zh) | 2022-01-21 |
| WO2020215155A8 (en) | 2020-11-26 |
| EA202192903A1 (ru) | 2022-02-09 |
| EP3959209A4 (en) | 2022-12-28 |
| JP2022530028A (ja) | 2022-06-27 |
| AU2020264143A1 (en) | 2021-10-28 |
| CA3137191A1 (en) | 2020-10-29 |
| EP3959209A1 (en) | 2022-03-02 |
| SG11202111003UA (en) | 2021-11-29 |
| TWI862582B (zh) | 2024-11-21 |
| US20220204494A1 (en) | 2022-06-30 |
| WO2020215155A1 (en) | 2020-10-29 |
| US12325700B2 (en) | 2025-06-10 |
| BR112021021106A2 (pt) | 2021-12-14 |
| IL287394A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4057920C0 (en) | TRANSCATHETER INTRODUCTION OF A MEDICAL IMPLANT | |
| CL2019003188A1 (es) | Sales de inhibidor de pi3k y procesos de preparación. (divisional solicitud 201702179) | |
| EP3943417A4 (en) | STORAGE ROBOT | |
| EP3768187A4 (en) | FAST AND PRECISE TOOL CHANGE MECHANISM FOR INTRAOCULAR ROBOTIC SURGICAL SYSTEMS | |
| HUS000506I2 (hu) | Tigilanol tiglát, geometriai izomerjei, sztereoizomerjei és gyógyászatilag, mezõgazdaságilag vagy kártevõirtóként elfogadható sói | |
| SMT201200052B (it) | Dispositivo per l'erogazione di lenti intraocularidotato di una cartuccia con un rivestimento inter no | |
| MA52424A (fr) | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide | |
| SMP201000002B (it) | Sali dell'inibitore di chinasi janus (R)-3-(4-(7H-pirrolo[2,3-D]pirimidin-4-IL)-1H-pirazoli-1-IL)-3-ciclopentilpropanonitrile | |
| IL287394A (en) | In the s4 crystal form of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-(cis-2,6-dimethylmorpholino)methyl)styrol)- 1 h-imidazol-6-yl)-5' -Methoxyspirio[cyclopropane-1,3'-indoline]-2'-one fumarate | |
| DOP2018000190A (es) | Nueva forma cristalina de sal de 1(5(2,4difluorfenil)1((3fluorfenil)sulfonil)4metoxi1hpirrol3il)nmetilmetanamina | |
| EP3927729A4 (en) | Therapeutic antibody formulation | |
| EP3481428A4 (en) | ADHESIVE ORAL SOLDERED FOILS FOR CARING THE MOUTH CARE | |
| EP3849562A4 (en) | COMBINATION COMPOSITIONS WITH A BETA-LACTAMASE INHIBITOR | |
| MA55976A (fr) | Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide | |
| EP3992176A4 (en) | EP2 ANTAGONIST | |
| EP3986415A4 (en) | IBOGAIN FORMULATIONS | |
| ITGE20030014A1 (it) | Macchina automatica con attivazione a moneta per la fabbricazione e la distribuzione estemporanea di dosi | |
| EP3932977A4 (en) | SEALING FILM | |
| EP3903723A4 (en) | Dental implant handset | |
| EP3794015A4 (en) | ACTIVATING AGENT | |
| HK40070200A (en) | Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate | |
| EP3302466A4 (en) | 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases | |
| MA53009A (fr) | Agents inhibiteurs d'ask1 | |
| EP3923893A4 (en) | HYGIENE PRODUCTS | |
| EP3937991A4 (en) | STERILIZER FOR PROSTHETIC ACCESSORIES |